Patent application number | Description | Published |
20080257754 | METHOD AND APPARATUS FOR ENTRY OF SPECIMENS INTO A MICROFLUIDIC DEVICE - A microfluidic device for analyzing biological samples is provided with a sample inlet section including an inlet port, a capillary passageway communication with the inlet port and with an inlet chamber. The inlet chamber includes means for uniformly distributing the sample liquid across the inlet chamber and purging the air initially contained therein. | 10-23-2008 |
20090004059 | METHOD AND APPARATUS FOR PRECISE TRANSFER AND MANIPULATION OF FLUIDS BY CENTRIFUGAL AND OR CAPILLARY FORCES - A micro-liter liquid sample, particularly a biological sample, is analyzed in a device employing centrifugal and capillary forces. The sample is moved through one or more sample wells arrayed within a small flat chip via interconnecting capillary passageways. The passageways may be either hydrophobic or hydrophilic and may include hydrophobic or hydrophilic capillary stops. | 01-01-2009 |
20090041627 | PACKAGING OF MICROFLUIDIC DEVICES - A microfluidic device containing liquid reagents having an extended shelf life contains the liquid reagents in micro-reservoirs that limit the escape of moisture to less than 10% over the shelf life of the device. The micro-reservoir preferably is made of polypropylene and covered with a metallized plastic film. | 02-12-2009 |
20090143275 | ADIPONECTIN RECEPTOR FRAGMENTS AND METHODS OF USE - Methods are disclosed of treating diabetes, abnormal adipocyte activity, and insulin resistance using C-terminal fragments of adiponectin receptor R1. Methods of causing the secretion of insulin in healthy and diabetic patients using C-terminal fragments of adiponectin receptor R1 are also disclosed. In addition, methods are disclosed of increasing the insulin levels in healthy patients using C-terminal fragments of adiponectin receptor R1. In addition, methods of treating abnormal adipocyte activity, treating metabolic syndrome, causing insulin secretion, increasing insulin levels, inhibiting insulin degradation enzyme, treating Alzheimer's disease, treating cardiovascular disease associated with adiponectin levels, inhibiting ADAM-17 enzyme, treating a condition associated with TNF-alpha, and treating a condition associated with HER2-neu are disclosed. Compositions, dosage forms, and kits are also disclosed. | 06-04-2009 |
20100093109 | PIEZO DISPENSING OF A DIAGNOSTIC LIQUID INTO MICROFLUIDIC DEVICES - Assays in which samples of biological fluids are dispensed into the inlet port of a microfluidic device are improved in the accuracy and repeatability by dispensing the biological sample and/or associated liquids in small droplets and at timed intervals to control the operation of the microfluidic device. | 04-15-2010 |
20100172801 | METHOD FOR UNIFORM APPLICATION OF FLUID INTO A REACTIVE REAGENT AREA - Analytical results obtained with microfluidic devices are improved by providing structural features in areas containing dry supported reagents, the structural features directing the flow of a sample over the area in a predetermined uniform manner and facilitating the purging of air. | 07-08-2010 |
20100184110 | PREDICTIVE DIAGNOSTICS FOR KIDNEY DISEASE - The present invention relates to markers for kidney disease. | 07-22-2010 |
20100239137 | Two Dimensional Imaging of Reacted Areas On a Reagent - A system for reading an assay includes a camera and a processor. The assay is used as a test for the presence or absence of a reaction between a sample and a reagent. The assay is defined by a test area and a background area. The test area is, preferably, substantially circular with a diameter between about 0.1 mm and about 5 mm. The camera simultaneously captures a two-dimensional image of the test area and the background area. The processor determines a first color response from the background area and a second color response from the test area. The processor then calibrates the second color response according to the first color response and generates a result of the test according to the second color response. The system may also include a uniform field illuminator that provides a substantially uniform level of illumination across the assay. | 09-23-2010 |
20110111522 | NON-VISIBLE DETECTABLE MARKING FOR MEDICAL DIAGNOSTICS - Sample media for the analysis of analytes in a fluid test sample includes a carrier, at least one test field on the surface of the carrier including at least one reagent reactive with the analytes and capable of providing a detectable response. A non-visible bar code formed by at least two distinct non-visible marker fields is located on the carrier. The marker fields are configured to reflect electro-magnetic (EM) radiation within one or more ranges of non-visible wavelengths to form a coded sequence of reflectances correlated to identification of the sample media. | 05-12-2011 |
20110118141 | Disease Specific Diagnostic Aid - A disease specific panel having at least one primary test for different analytes that are relevant for either early detection of a primary disease or management of patients already diagnosed with said primary disease. The panel also includes at least one secondary test which is relevant for detection of a co-morbid condition or complications of the primary disease. Generally, the primary and secondary tests are disposed on a support surface. The disease specific panel is different from the prior art creening tests in that there are no tests included in the panel whose results are not relevant or do not relate to either primary disease or a co-morbid condition or complications of the primary disease. The disease specific panel may also include systems and methods utilizing algorithms for creating and outputting diagnostic aids, as well as warnings about the presence of possible sample interferants, especially those commonly associated with the subject disease of the panel. | 05-19-2011 |
20110149277 | Multi-Layer Slides for Analysis of Urine Sediments - Visual analysis of urine samples is carried out with the use of a slide consisting of three layers containing an enclosed viewing chamber which receives a urine sample deposited by pipette into an opening on the outer layer of the slide. From the inlet opening the sample enters an inlet chamber in the middle layer and passes through a capillary passageway into the viewing chamber where it is inspected for particles and sediments. | 06-23-2011 |
20110275104 | Device and Method for Detection of Humidity-Compromised Urine Test Strips - The timing of the reaction of moisture-sensitive reagents for detecting the presence of analytes, e.g. leukocytes in urine samples, is used to detect when the reagents have been compromised by excess humidity. The ratio of light reflectance at wavelengths characteristic of the products of reaction between the reagents and the analyte and an infra-red reference dye is measured at two preset times after a urine sample has been applied to a test strip and used to determine whether the reagents have been compromised by excessive humidity. The presence of unusually dark samples is determined from the reflected light at 470 and 625 nm in order to confirm that the test strips are humidity-compromised. | 11-10-2011 |
20110301089 | ADIPONECTIN RECEPTOR FRAGMENTS AND METHODS OF USE - Methods are disclosed of treating diabetes, abnormal adipocyte activity, and insulin resistance using C-terminal fragments of adiponectin receptor R1. Methods of causing the secretion of insulin in healthy and diabetic patients using C-terminal fragments of adiponectin receptor R1 are also disclosed. In addition, methods are disclosed of increasing the insulin levels in healthy patients using C-terminal fragments of adiponectin receptor R1. In addition, methods of treating abnormal adipocyte activity, treating metabolic syndrome, causing insulin secretion, increasing insulin levels, inhibiting insulin degradation enzyme, treating Alzheimer's disease, treating cardiovascular disease associated with adiponectin levels, inhibiting ADAM-17 enzyme, treating a condition associated with TNF-alpha, and treating a condition associated with HER2-neu are disclosed. Compositions, dosage forms, and kits are also disclosed. | 12-08-2011 |
20120135916 | MONOMERIC AND DIMERIC FORMS OF ADIPONECTIN RECEPTOR FRAGMENTS AND METHODS OF USE - Methods are disclosed for determining progression of a condition, onset of a condition, or efficacy of treatment of a condition characterized by an adipocyte imbalance in a patient. In addition, methods are disclosed of treating diabetes, abnormal adipocyte activity, and insulin resistance using monomeric, homodimeric, and heterodimeric forms of certain C-terminal fragments of adiponectin receptor. In addition, methods of treating abnormal adipocyte activity, treating metabolic syndrome, causing insulin secretion, increasing insulin levels, inhibiting insulin degradation enzyme, treating Alzheimer's disease, treating cardiovascular disease associated with adiponectin levels, inhibiting ADAM-17 enzyme, inhibiting a protease, treating a condition associated with TNF-alpha, and treating a condition associated with HER2-neu are disclosed. Compositions, dosage forms, and kits are also disclosed. | 05-31-2012 |
20130004988 | DISPENSING OF A DIAGNOSTIC LIQUID ONTO A DIAGNOSTIC REAGENT - Biological fluid samples are deposited by methods that produce a uniform layer of the sample over a reagent-containing surface. In one embodiment, a nozzle having multiple openings is used to deposit a sample over the reagent-containing surface simultaneously. In an alternative embodiment, single droplets of the sample are deposited in a pattern on the surface, preferably in a sequence of parallel lines. The reaction between the biological sample and the reagents is read from a spectrographic image of the reagent-containing surface obtained by optical methods. | 01-03-2013 |
20130041236 | SAMPLE ANALYSIS SYSTEM AND METHOD OF USE - A sample collection device having a sample container and microfluidic device having one or more microfluidic circuits, the system for analyzing biological samples. The microfluidic device has a sample inlet port, a microconduit in communication with the inlet port and with reaction chamber. The reaction chamber is connected to an air vent via another microconduit. Air may be vented from the microfluidic circuit via the air vent of the microfluidic circuit via an air vent in the sample container. | 02-14-2013 |
20130287630 | HYDROPHILIC COATING FOR NONPOROUS SURFACES AND MICROFLUIDIC DEVICES INCLUDING SAME - A coating formula and method for surface coating non-porous surfaces. Microfluidic devices including said coating achieve desired properties including increased hydrophilicity, improved adhesion, stability and optical clarity. | 10-31-2013 |
20140336084 | COATED SUBSTRATES FOR HIGH ENERGY CAPTURE PHASE BINDING AND METHODS OF PRODUCTION AND USE THEREOF - A substrate, which is useful for performing biological, chemical and diagnostic assays, and a method for preparing the substrate are provided. The substrate has an upper surface with a coating disposed thereon. The coating comprises a charged polymer, a non-ionic polyether, and a silicate compound. The substrate can increase capture phase binding and reduce non-specific binding of biomolecules for a biological microarray. | 11-13-2014 |
20150038426 | Monomeric and Dimeric Forms of Adiponectin Receptor Fragments and Methods of Use - Methods are disclosed for determining progression of a condition, onset of a condition, or efficacy of treatment of a condition characterized by an adipocyte imbalance in a patient. In addition, disclosed herein are methods of treating diabetes, abnormal adipocyte activity, and insulin resistance using monomeric, homodimeric, and heterodimeric forms of certain C-terminal fragments of adiponectin receptor. In addition, methods of treating abnormal adipocyte activity, treating metabolic syndrome, causing insulin secretion, increasing insulin levels, inhibiting insulin degradation enzyme, treating Alzheimer's disease, treating cardiovascular disease associated with adiponectin levels, inhibiting ADAM-17 enzyme, inhibiting a protease, treating a condition associated with TNF-alpha, and treating a condition associated with HER | 02-05-2015 |